Future research, including pre-clinical in vivo experiments, is required to further dissect the types of HR-deficient cancers likely to be the most suitable for targeting CtIP activities via CBX4 and how this might synergise with other DDR inhibitors, chemotherapeutics, and/or radiotherapy. The gene discussed is CBX4; the disease is cancer.